Modified Chemotherapy With Carmustine, Cytarabine, Cyclophosphamide, and 6-Thioguanine (BACT) and Autologous Bone Marrow Transplantation in 24 Poor-Risk Patients With Acute Lymphoblastic Leukemia1
| Autor: | Kalifa C, G. Novakovitch, D. Maraninchi, Jean Lemerle, J. L. Pico, Y. Carcassonne, Ellen Benhamou, B. Mascret, R. Ghalie, Catherine Patte, Hartmann O, M. Hayat, F. Beaujean |
|---|---|
| Rok vydání: | 1986 |
| Předmět: |
Cancer Research
medicine.medical_specialty Chemotherapy Carmustine Cyclophosphamide business.industry medicine.medical_treatment medicine.disease Chemotherapy regimen Gastroenterology Regimen Oncology Maintenance therapy Internal medicine Acute lymphocytic leukemia Immunology medicine Cytarabine business medicine.drug |
| Zdroj: | JNCI: Journal of the National Cancer Institute. |
| ISSN: | 1460-2105 |
| DOI: | 10.1093/jnci/76.6.1289 |
| Popis: | Twenty-four poor-risk patients with acute lymphoblastic leukemia received a modified regimen of carmustine, cytarabine, cyclophosphamide, and 6-thioguanine (BACT) followed by autologous bone marrow transplantation (ABMT). Nineteen patients were in second or subsequent complete remission (CR) when treated with this regimen; 3 died early, 2 died of pneumonia in CR, 11 relapsed within 3 months (median), and 3 remain in CR with no maintenance therapy 14-24 months after ABMT. Of the 5 patients with measurable disease who were treated, 3 had CR and 1 remains in CR without maintenance therapy more than 28 months after ABMT. The toxicity of this regimen was acceptable, but late pulmonary toxic effects remain a major concern. These results are poor in terms of efficacy, and new effective methods of eradicating acute lymphoblastic leukemia in patients with poor prognosis should be investigated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|